BDF
CPRX

Balasa Dinverno & Foltz’s Catalyst Pharmaceutical CPRX Stock Holding History

Balasa Dinverno & Foltz’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,000
Closed -$45K – 202
2015
Q3 		$45K Buy
+15,000
New +$64.7K 0.01% 191

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balasa Dinverno & Foltz's CPRX Position: Q4 2015 in Review

Balasa Dinverno & Foltz sold out of Catalyst Pharmaceutical (CPRX) in Q4 2015, closing a stake of 15,000 shares — an estimated $45K sold.

Balasa Dinverno & Foltz first reported a position in CPRX in Q3 2015 and held it in 1 quarter. The position peaked at $45K in Q3 2015. 85 funds tracked by Wall St. Rank hold CPRX as of Q4 2015.

  • Balasa Dinverno & Foltz reported no remaining Catalyst Pharmaceutical position as of Q4 2015 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 15,000 Catalyst Pharmaceutical shares in Q4 2015, an estimated $45K.
  • Balasa Dinverno & Foltz first reported a position in Catalyst Pharmaceutical in Q3 2015 and held it in 1 quarter.
  • Balasa Dinverno & Foltz's Catalyst Pharmaceutical position peaked at $45K in Q3 2015.
  • 85 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2015.

Based on Balasa Dinverno & Foltz's 13F filing for Q4 2015, filed 10 Feb 2016.